Recombinant CCR4 (Mogamulizumab Biosimilar) 抗体
-
- 抗原 See all CCR4 (Mogamulizumab Biosimilar) products
- CCR4 (Mogamulizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- Chimeric
-
标记
- This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated
-
应用范围
- Depletion (Dep)
- 原理
- Anti-CCR4 [KW-0761 (Mogamulizumab)], Mouse IgG2a, kappa
- 特异性
- This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
- 产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- 纯化方法
- Protein A affinity purified
- 免疫原
- This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
- 克隆位点
- KW-0761
- 亚型
- IgG2a kappa
-
anti-CCR4 (Mogamulizumab Biosimilar) antibody
Research Grade 适用: 人 FACS 宿主: Humanized Monoclonal unconjugated
anti-CCR4 (Mogamulizumab Biosimilar) antibody适用: 人 Dep 宿主: 兔 Chimeric KW-0761 unconjugated Recombinant Antibody
-
- 应用备注
- The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
- 说明
-
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- 限制
- 仅限研究用
-
- 浓度
- 1 mg/mL
- 缓冲液
- PBS with 0.02 % Proclin 300.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- 抗原
- CCR4 (Mogamulizumab Biosimilar)
- Abstract
- CCR4 (Mogamulizumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
- CD194, CKR-4, CCR-4, CCR4, K5-5
- UniProt
- P51679
-
